Skip to main content
Premium Trial:

Request an Annual Quote

RAN, Fluigent Ink Distribution Agreement for Europe

NEW YORK (GenomeWeb) – Fluigent will distribute RAN Biotechnologies' products in Europe, RAN announced today.

RAN is a provider of chemicals for microfluidic and biotech applications, including fluorosurfactants and microfluidic surface coatings for stabilizing water-in-oil emulsions for droplet microfluidics and encapsulating biological molecules, such as DNA, RNA, cells, and proteins. According to the Beverly, Mass.-based firm, droplet microfluidics is an alternative to lab-on-a-chip technology that is compatible with many chemicals and biological molecules.

"Our expertise in synthetic and surface chemistry in general and in surfactants in particular allows us to develop advanced materials for microfluidics," RAN Founder and President Roger Nassar said in a statement. "Partnering with Fluigent is a major step in our exposure efforts in Europe … [and] will help us to reach a wider microfluidic market and allow us to be part of important new technologies by advancing lab-on-a-chip applications."

Fluigent is headquartered in Paris and develops, manufactures, and commercializes microfluidic flow control and fluid handling solutions.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.